精鼎医药成立早期临床研究联盟,扩大在大中华地区的Ⅰ期临床研究能力

2019-09-16 佚名 MedSci

2019年9月16日,,精鼎医药宣布与北大医疗鲁中医院、四川大学华西医疗中心和上海徐汇中心医院三家知名医疗机构结成联盟,为在中国进行Ⅰ期临床试验的医药企业提供更高水平的支持。作为全球创新疗法开发领导者,精鼎医药提供从临床到商业化的全流程解决方案,以加快创新疗法的开发和应用,助力提高全球健康水平。 精鼎医药执行副总裁兼首席临床研究服务官Gadi Saarony表示:“近年来,我们看到无论是针对健

2019年9月16日,,精鼎医药宣布与北大医疗鲁中医院、四川大学华西医疗中心和上海徐汇中心医院三家知名医疗机构结成联盟,为在中国进行Ⅰ期临床试验的医药企业提供更高水平的支持。作为全球创新疗法开发领导者,精鼎医药提供从临床到商业化的全流程解决方案,以加快创新疗法的开发和应用,助力提高全球健康水平。

精鼎医药执行副总裁兼首席临床研究服务官Gadi Saarony表示:“近年来,我们看到无论是针对健康受试者还是患者,在中国开展的I期临床试验数量都在持续增长。尽管中国存在着巨大的机遇,但许多企业难以拥有能够快速且有效开展早期临床研究所需的本土化基础设施,而从长远来看,这是影响成功的关键因素之一。通过与中国本土机构建立合作伙伴关系,精鼎医药能够为快速启动和执行临床研究提供强有力的支持,同时凭借我们在早期临床药理学方面的专长,以及在项目管理、数据管理和监管咨询方面的实力,我们致力于为客户提供行之有效的策略,助其在中国取得成功。”

在成功完成若干项Ⅰ期临床试验,并与上述中国本土医疗机构签订合作协议和建立运营体系之后,精鼎医药中国早期临床研究联盟正式成立。该联盟搭载精鼎医药在大中华地区的专业知识和技术,为全球和本土生物制药公司提供:

1,务实的研究能力、经验丰富的首席研究员,以及超过250个临床研究床位
2,利用本地资源快速启动和执行研究项目的能力
3,中国本土的临床药理学专家和项目经理,以简化沟通和流程
4,精鼎医药的专业支持,以满足当地的伦理学应用和监管要求
5,经验丰富的中国定量临床开发/数据管理/生物统计学/规划/医学写作团队,提供完整的早期临床阶段解决方案。

近期,精鼎医药被行业标准研究(Industry Standard Research, ISR)的2019年度CRO品质标准报告评为Ⅰ期临床开发的行业领导者。目前,精鼎医药在大中华区拥有8个办事处,共1700多名员工。在亚太地区,精鼎医药拥有8000多名员工。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1652936, encodeId=9bc0165293655, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sat Aug 22 23:20:00 CST 2020, time=2020-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801144, encodeId=d0501801144a0, content=<a href='/topic/show?id=76b5e3439fc' target=_blank style='color:#2F92EE;'>#研究能力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73439, encryptionId=76b5e3439fc, topicName=研究能力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sat Mar 28 22:20:00 CST 2020, time=2020-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950409, encodeId=ca2419504090b, content=<a href='/topic/show?id=c53ce6612b8' target=_blank style='color:#2F92EE;'>#精鼎医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76612, encryptionId=c53ce6612b8, topicName=精鼎医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ed3112, createdName=echonoir, createdTime=Sat Apr 25 06:20:00 CST 2020, time=2020-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409892, encodeId=16f7140989257, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Wed Sep 18 13:20:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496671, encodeId=ce2914966e129, content=<a href='/topic/show?id=bbd780e4884' target=_blank style='color:#2F92EE;'>#联盟#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80748, encryptionId=bbd780e4884, topicName=联盟)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7fc9269968, createdName=zexyw04, createdTime=Wed Sep 18 13:20:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372826, encodeId=ddc63e282635, content=谢谢了学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Tue Sep 17 06:30:43 CST 2019, time=2019-09-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1652936, encodeId=9bc0165293655, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sat Aug 22 23:20:00 CST 2020, time=2020-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801144, encodeId=d0501801144a0, content=<a href='/topic/show?id=76b5e3439fc' target=_blank style='color:#2F92EE;'>#研究能力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73439, encryptionId=76b5e3439fc, topicName=研究能力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sat Mar 28 22:20:00 CST 2020, time=2020-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950409, encodeId=ca2419504090b, content=<a href='/topic/show?id=c53ce6612b8' target=_blank style='color:#2F92EE;'>#精鼎医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76612, encryptionId=c53ce6612b8, topicName=精鼎医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ed3112, createdName=echonoir, createdTime=Sat Apr 25 06:20:00 CST 2020, time=2020-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409892, encodeId=16f7140989257, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Wed Sep 18 13:20:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496671, encodeId=ce2914966e129, content=<a href='/topic/show?id=bbd780e4884' target=_blank style='color:#2F92EE;'>#联盟#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80748, encryptionId=bbd780e4884, topicName=联盟)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7fc9269968, createdName=zexyw04, createdTime=Wed Sep 18 13:20:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372826, encodeId=ddc63e282635, content=谢谢了学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Tue Sep 17 06:30:43 CST 2019, time=2019-09-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1652936, encodeId=9bc0165293655, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sat Aug 22 23:20:00 CST 2020, time=2020-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801144, encodeId=d0501801144a0, content=<a href='/topic/show?id=76b5e3439fc' target=_blank style='color:#2F92EE;'>#研究能力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73439, encryptionId=76b5e3439fc, topicName=研究能力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sat Mar 28 22:20:00 CST 2020, time=2020-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950409, encodeId=ca2419504090b, content=<a href='/topic/show?id=c53ce6612b8' target=_blank style='color:#2F92EE;'>#精鼎医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76612, encryptionId=c53ce6612b8, topicName=精鼎医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ed3112, createdName=echonoir, createdTime=Sat Apr 25 06:20:00 CST 2020, time=2020-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409892, encodeId=16f7140989257, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Wed Sep 18 13:20:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496671, encodeId=ce2914966e129, content=<a href='/topic/show?id=bbd780e4884' target=_blank style='color:#2F92EE;'>#联盟#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80748, encryptionId=bbd780e4884, topicName=联盟)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7fc9269968, createdName=zexyw04, createdTime=Wed Sep 18 13:20:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372826, encodeId=ddc63e282635, content=谢谢了学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Tue Sep 17 06:30:43 CST 2019, time=2019-09-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1652936, encodeId=9bc0165293655, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sat Aug 22 23:20:00 CST 2020, time=2020-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801144, encodeId=d0501801144a0, content=<a href='/topic/show?id=76b5e3439fc' target=_blank style='color:#2F92EE;'>#研究能力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73439, encryptionId=76b5e3439fc, topicName=研究能力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sat Mar 28 22:20:00 CST 2020, time=2020-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950409, encodeId=ca2419504090b, content=<a href='/topic/show?id=c53ce6612b8' target=_blank style='color:#2F92EE;'>#精鼎医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76612, encryptionId=c53ce6612b8, topicName=精鼎医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ed3112, createdName=echonoir, createdTime=Sat Apr 25 06:20:00 CST 2020, time=2020-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409892, encodeId=16f7140989257, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Wed Sep 18 13:20:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496671, encodeId=ce2914966e129, content=<a href='/topic/show?id=bbd780e4884' target=_blank style='color:#2F92EE;'>#联盟#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80748, encryptionId=bbd780e4884, topicName=联盟)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7fc9269968, createdName=zexyw04, createdTime=Wed Sep 18 13:20:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372826, encodeId=ddc63e282635, content=谢谢了学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Tue Sep 17 06:30:43 CST 2019, time=2019-09-17, status=1, ipAttribution=)]
    2019-09-18 cathymary
  5. [GetPortalCommentsPageByObjectIdResponse(id=1652936, encodeId=9bc0165293655, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sat Aug 22 23:20:00 CST 2020, time=2020-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801144, encodeId=d0501801144a0, content=<a href='/topic/show?id=76b5e3439fc' target=_blank style='color:#2F92EE;'>#研究能力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73439, encryptionId=76b5e3439fc, topicName=研究能力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sat Mar 28 22:20:00 CST 2020, time=2020-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950409, encodeId=ca2419504090b, content=<a href='/topic/show?id=c53ce6612b8' target=_blank style='color:#2F92EE;'>#精鼎医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76612, encryptionId=c53ce6612b8, topicName=精鼎医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ed3112, createdName=echonoir, createdTime=Sat Apr 25 06:20:00 CST 2020, time=2020-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409892, encodeId=16f7140989257, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Wed Sep 18 13:20:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496671, encodeId=ce2914966e129, content=<a href='/topic/show?id=bbd780e4884' target=_blank style='color:#2F92EE;'>#联盟#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80748, encryptionId=bbd780e4884, topicName=联盟)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7fc9269968, createdName=zexyw04, createdTime=Wed Sep 18 13:20:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372826, encodeId=ddc63e282635, content=谢谢了学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Tue Sep 17 06:30:43 CST 2019, time=2019-09-17, status=1, ipAttribution=)]
    2019-09-18 zexyw04
  6. [GetPortalCommentsPageByObjectIdResponse(id=1652936, encodeId=9bc0165293655, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sat Aug 22 23:20:00 CST 2020, time=2020-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801144, encodeId=d0501801144a0, content=<a href='/topic/show?id=76b5e3439fc' target=_blank style='color:#2F92EE;'>#研究能力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73439, encryptionId=76b5e3439fc, topicName=研究能力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sat Mar 28 22:20:00 CST 2020, time=2020-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950409, encodeId=ca2419504090b, content=<a href='/topic/show?id=c53ce6612b8' target=_blank style='color:#2F92EE;'>#精鼎医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76612, encryptionId=c53ce6612b8, topicName=精鼎医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ed3112, createdName=echonoir, createdTime=Sat Apr 25 06:20:00 CST 2020, time=2020-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409892, encodeId=16f7140989257, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Wed Sep 18 13:20:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496671, encodeId=ce2914966e129, content=<a href='/topic/show?id=bbd780e4884' target=_blank style='color:#2F92EE;'>#联盟#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80748, encryptionId=bbd780e4884, topicName=联盟)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7fc9269968, createdName=zexyw04, createdTime=Wed Sep 18 13:20:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372826, encodeId=ddc63e282635, content=谢谢了学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Tue Sep 17 06:30:43 CST 2019, time=2019-09-17, status=1, ipAttribution=)]
    2019-09-17 txqjm

    谢谢了学习

    0

相关资讯

精鼎医药携手CLARINESS 提升中国临床试验患者招募能力及患者参与度

2019年6月25日,全球创新疗法开发领导者精鼎医药今日宣布与全球领先的患者招募公司CLARINESS建立战略伙伴关系,助力加速中国的临床试验患者招募,提升患者参与度。近年来,在利好政策的支持和鼓励下,中国的临床试验数量急剧上升。根据国家药品监督管理局药品审评中心药物临床试验登记与信息公示平台的数据显示,2018年登记(获得CTR号)的临床试验总数为2579,相比2017年大幅增加了885个临床试

精鼎医药在港成立Health Advances亚洲分公司拓展亚太市场业务

2019年7月23日,精鼎医药近日宣布其旗下医疗战略咨询公司Health Advances(医疗进阶)在中国香港成立亚洲分公司,以拓展其在亚太地区的业务范围,进一步提升在这一地区优化药物开发和商业化方案的能力。作为全球创新疗法开发领导者,精鼎医药致力于提供从临床到商业化的全流程解决方案,加快创新疗法的开发和运用,提高全球健康水平。精鼎医药在亚太地区已有20多年的历史,此次Health Advanc

临床研究革新势在必行:以数字化转型加速药物开发创新

药物开发创新是一个周期长、高投资、高风险的过程,药物开发通常需要10年到15年的时间,投入资金会达到5到10亿美元。这个过程对于药企来说都是一个巨大的挑战,同时也是沉重的负担。各个药企现在正在积极地探索利用新的创新手段,提高临床试验、临床开发的效率,以及提高新产品上市的概率,这是所有制药企业所面临的共同的挑战。作为全球领先的生物制药服务创新企业,精鼎医药致力于在中国和全球推动实施创新,其旗下的